Pleural and Mediastinal Malignancies最新文献_第8页

Targeting of CSF1R abrogates Lewis Lung adenocarcinoma-induced malignant pleural effusion 靶向CSF1R可消除Lewis肺腺癌诱导的恶性胸腔积液

Pleural and Mediastinal Malignancies Pub Date : 2018-09-15 DOI: 10.1183/13993003.congress-2018.pa2861

Sophia F. Magkouta, C. Kosti, Photene C. Vaitsi, Apostolos G. Pappas, Charalampos Moschos, M. Iliopoulou, K. Psarra, I. Kalomenidis

引用次数: 1

Comparison of pleural fluid pH measurements: blood gas analyzer, pH indicator stick, litmus paper, and point-of-care testing for blood gases 比较胸膜液pH值测量:血气分析仪，pH指示剂棒，石蕊试纸，和点护理测试的血气

Pleural and Mediastinal Malignancies Pub Date : 2018-09-15 DOI: 10.1183/13993003.congress-2018.pa2872

Sang-Ha Kim, Beomsu Shin, S. Lee, M. Lee, W. Lee, S. Yong

引用次数: 1

Does talc increase risk of non-draining septated pleural effusion after indwelling pleural catheter insertion? 滑石粉是否会增加留置胸膜导管后发生非引流性分隔性胸腔积液的风险?

Pleural and Mediastinal Malignancies Pub Date : 2018-09-15 DOI: 10.1183/13993003.CONGRESS-2018.OA498

R. Asciak, R. Mercer, R. Hallifax, Maged Hassan, N. Kanellakis, J. Wrightson, I. Psallidas, N. Rahman

{"title":"Does talc increase risk of non-draining septated pleural effusion after indwelling pleural catheter insertion?","authors":"R. Asciak, R. Mercer, R. Hallifax, Maged Hassan, N. Kanellakis, J. Wrightson, I. Psallidas, N. Rahman","doi":"10.1183/13993003.CONGRESS-2018.OA498","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.OA498","url":null,"abstract":"Non-draining septated pleural effusions limit effective drainage via indwelling pleural catheters (IPC). Aim: To retrospectively analyse whether previous talc pleurodesis attempt increases chances of a non-draining septated pleural effusion after IPC insertion. Method IPC outcomes and complications for IPC insertions were analysed. ‘MPE group’ were IPC insertions for malignant pleural effusion(MPE), ‘non-MPE group’ were IPC insertions for hepatic hydrothorax(3% overall), benign pleuritis(3%), heart failure(2%), other(2.5%). Mesothelioma cases were analysed separately in view of the possibility of increased pleural tumour-induced fibrin deposition within the pleural space. Results: 202 IPC insertions were analysed: MPE group(n=181), mean age 68 years(SD 13.9), 48% female (n=87); non-MPE group(n=21), mean age 70 years(SD 10.8) (p=0.4), 29%(n=6) female (p=0.09). Overall, 2.7% (n=2) and 4.7% (n=6) of patients with and without prior talc respectively developed non-draining septated pleural effusion (p=0.47). Of these, 2(25%) patients had heterogeneously septated pleural effusion at IPC insertion, and they had not received prior talc, 75%(n=6) developed septation while IPC was in situ. Conclusion: There was no significant difference in rates of non-draining septated effusions between patients who had received prior talc and those who had not, although limited by the retrospective study design and small numbers.","PeriodicalId":20113,"journal":{"name":"Pleural and Mediastinal Malignancies","volume":"70 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90098888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessing breathlessness following pleural fluid drainage using the Visual Analogue Scale for Dyspnoea(VASD) over 1 week(7-DVQ) 使用呼吸困难视觉模拟量表(VASD)评估胸腔液引流后1周内的呼吸困难(7-DVQ)

Pleural and Mediastinal Malignancies Pub Date : 2018-09-15 DOI: 10.1183/13993003.CONGRESS-2018.PA2891

R. Banka, E. Mishra

{"title":"Assessing breathlessness following pleural fluid drainage using the Visual Analogue Scale for Dyspnoea(VASD) over 1 week(7-DVQ)","authors":"R. Banka, E. Mishra","doi":"10.1183/13993003.CONGRESS-2018.PA2891","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA2891","url":null,"abstract":"Introduction: VASD is a patient reported outcome assessing dyspnea intensity, consisting of a 100mm horizontal line anchored at 0mm with ‘Not breathless at all’ and at 100mm with ‘Worst possible breathlessness’. Although it is a validated measure of dyspnea change with pleural fluid drainage, the optimal duration of measurement following aspiration is not well established and there appears to be a significant placebo effect after 24 hours. Aim: To assess whether routine measurement of 7-DVQ post pleural aspiration is i.acceptable to patients and has a good(>70%)response rate ii. Assess relationship between volume of pleural fluid drained and mean 7-DVQ. Methods: Between Sept 2017 and Jan 2018, consecutive patients undergoing pleural aspiration in pleural clinic at NNUH were enrolled to fill up 7-DVQ. Baseline VASD was recorded before the aspiration and subsequently the patient was asked to complete it at home for 7 days. Results: Of 23 patients who underwent aspiration,17 questionnaires were returned, of which data for analysis were available from 16 patients. Demographics are summarised in Table 1. Mean VASD at baseline and at end of 7 days was 64 mm(SD 28) and 46 mm(SD 21)respectively. Mean decrease in VASD at end of 7 days was 19 mm(SD 14). Correlation between volume of fluid aspirated and decrease in 7-DVQ was 0.5(p=0.03) Conclusion: This study shows that 7-DVQ as a measure to quantify change in dyspnea post aspiration correlates well with amount of fluid aspirated and baseline dyspnea.A response rate of 73% suggests that 7-DVQ is an acceptable measure for patients.","PeriodicalId":20113,"journal":{"name":"Pleural and Mediastinal Malignancies","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77719372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In the era of personalised medicine, is pleural fluid cytology sufficient for oncological treatment? 在个体化医疗时代，胸膜液细胞学检查是否足以用于肿瘤治疗?

Pleural and Mediastinal Malignancies Pub Date : 2018-09-15 DOI: 10.1183/13993003.congress-2018.pa2860

R. Mercer, D. McCracken, R. Asciak, R. Hallifax, Maged Hassan, E. Bedawi, N. Rahman

{"title":"In the era of personalised medicine, is pleural fluid cytology sufficient for oncological treatment?","authors":"R. Mercer, D. McCracken, R. Asciak, R. Hallifax, Maged Hassan, E. Bedawi, N. Rahman","doi":"10.1183/13993003.congress-2018.pa2860","DOIUrl":"https://doi.org/10.1183/13993003.congress-2018.pa2860","url":null,"abstract":"Introduction: Pleural fluid (PF) cytology was previously sufficient to guide oncological treatment. In the current field of personalised medicine, this may not be the case and it is frequently necessary to obtain a tissue sample even when the PF cytology demonstrates malignant cells. This raises the question of the role of PF cytology in the diagnostic pathway of patients with malignant pleural effusion. Aims & Method: All patients who had a procedure performed by the pleural service between 2015 - 2017 were included. Those with PF demonstrating malignant cells were reviewed to determine whether further tissue was required. Those with concurrent pleural histological samples were excluded. Results: 107 patients had positive PF cytology. No further testing was needed in 49 patients; 33 already had a pathological diagnosis and 16 were too unwell for treatment or followed up elsewhere. PF was sufficient to test for receptor or mutation status in 33/58 (57%) patients, 19 (33%) required further pleural biopsies and 6 (10%) underwent alterative procedures to obtain tissue. 52/58 patients had adenocarcinoma cells in the PF. Conclusions: PF cytology was sufficient for definitive oncological treatment in 57% of patients. Further work is needed to determine characteristics which would highlight which patients are likely to need further tests to guide treatments and in which patients PF will be sufficient.","PeriodicalId":20113,"journal":{"name":"Pleural and Mediastinal Malignancies","volume":"101 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80468038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cisplatin/pemetrexed chemotherapy versus palliative care survival in malignant pleural mesothelioma 顺铂/培美曲塞化疗对恶性胸膜间皮瘤姑息治疗生存率的影响

Pleural and Mediastinal Malignancies Pub Date : 2018-09-15 DOI: 10.1183/13993003.congress-2018.pa2894

Ivan Škopljanac, Ivana Šegrt, K. Miše, Emilija Lozo Vukovac, Anita Tolic Biocina

{"title":"Cisplatin/pemetrexed chemotherapy versus palliative care survival in malignant pleural mesothelioma","authors":"Ivan Škopljanac, Ivana Šegrt, K. Miše, Emilija Lozo Vukovac, Anita Tolic Biocina","doi":"10.1183/13993003.congress-2018.pa2894","DOIUrl":"https://doi.org/10.1183/13993003.congress-2018.pa2894","url":null,"abstract":"Introduction: Malignant pleural mesothelioma is a rare tumour commonly associated with asbestos exposure however with increasing incidence and poor survival. The standard first-line chemotherapy regimen is the combination of cisplatin and pemetrexed, with median overall survival of 13 months. Other therapeutic options like surgery, radiation and immunotherapy are currently limited therefore patient s performance status and histological subtype are the only prognostic factors (Scherpereel A. et al. EurRespir J 2010;35: 479-95, Scherpereel A. EurRespir J.2017 Mar 15;49(3). Aim and Objectives: The aim of study was to compare the patient9s survival depending on whether they received chemotherapy or not. Methods: We identified retrospectively 24 patients diagnosed with pleural mesothelioma in Department of Pulmonology, Clinical Hospital Center Split, Croatia evaluating their management, whether they were treated by cisplatin/pemetrexed or solely palliative care as a result of poor performance status or refusal of any specific treatment. Kaplan-Meier survival analysis was used (MedCalc Software ver. 18). Results: The overall median survival (OS) time was 14,6 months. A pronounced OS benefit for palliative care versus cisplatin/pemetrexed was observed, 17 vs 8 months, respectively; HR, 0,3665 ; 95% CI, 0,14 to 0,90 ; P = 0,0047, Fig. 1. Conclusions: Chemotherapeutic treatment did not show better outcomes than solely palliative treatment. Future prospective randomized controlled studies are necessary to optimize the treatment of malignant mesothelioma.","PeriodicalId":20113,"journal":{"name":"Pleural and Mediastinal Malignancies","volume":"241 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91115564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of cisplatin and pemetrexed on 3D phenotypes of benign mesothelial and malignant pleural mesothelioma cells 顺铂和培美曲塞对良性胸膜间皮瘤和恶性胸膜间皮瘤细胞三维表型的影响

Pleural and Mediastinal Malignancies Pub Date : 2018-09-15 DOI: 10.1183/13993003.CONGRESS-2018.PA2895

Eleftherios D. Papazoglou, R. Jagirdar, E. Pitaraki, O. Kotsiou, C. Hatzoglou, K. Gourgoulianis, S. Zarogiannis

引用次数: 0

EBUS-TBNA for the diagnosis of intrathoracic lymphadenopathy in patients with previously diagnosed breast carcinoma EBUS-TBNA对既往乳腺癌患者胸内淋巴结病变的诊断价值

Pleural and Mediastinal Malignancies Pub Date : 2018-09-15 DOI: 10.1183/13993003.congress-2018.pa2892

N. Živković, A. Ljilja, Nina-Petra Novak, N. Tudorić

{"title":"EBUS-TBNA for the diagnosis of intrathoracic lymphadenopathy in patients with previously diagnosed breast carcinoma","authors":"N. Živković, A. Ljilja, Nina-Petra Novak, N. Tudorić","doi":"10.1183/13993003.congress-2018.pa2892","DOIUrl":"https://doi.org/10.1183/13993003.congress-2018.pa2892","url":null,"abstract":"The diagnostic method of endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA) for the confirmation of extrathoracic malignant disease dissemination into mediastinal lymph nodes has been proven as highly efficient (sensitivity 93%, specificity 100%). The aim of this research was to carry out a retrospective study of the medical records of patients with newly developed mediastinal/hilar lymphadenopathy (ML) and previously diagnosed extrathoracic malignant disease, select the patients with previously diagnosed breast carcinoma, and analyze the results of EBUS-TBNA. The retrospective, single-center clinical observational study was conducted in the period from January 2015 to August 2017, in which the EBUS-TBNA results were analyzed for 77 patients who had met the inclusion criteria. A malignant etiology of the ML was confirmed in 39/77 patients (50.64%). Patients with previously diagnosed breast carcinoma showed a divergence within this group. A malignant etiology of the ML was confirmed in 10/14 patients (71.42%), and a benign one in 3/14 patients (21.42%). In one patient with reactive lymphadenopathy and pulmonary parenchymal infiltration, primary lung carcinoma was confirmed by thoracotomy. Two patients showed signs of reactive/granulomatous ML during chemotherapy with paclitaxel, and in one patient sarcoidosi was confirmed. To conclude, in spite of the high percentage of a malignant etiology of newly developed ML in patients with previously diagnosed breast carcinoma, their cytological verification is necessary due to the possibility of a reactive/granulomatous lymph node reaction, especially in patients undergoing chemotherapy with paclitaxel.","PeriodicalId":20113,"journal":{"name":"Pleural and Mediastinal Malignancies","volume":"55 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73555500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Red cell distribution width value as a novel biomarker for exudative pleural fluid. 红细胞分布宽度值作为一种新的胸腔渗出液生物标志物。

Pleural and Mediastinal Malignancies Pub Date : 2018-09-15 DOI: 10.1183/13993003.congress-2018.pa2870

A. Sharifi, D. Amir

引用次数: 0

Rotation Aiding (RA’s) technique for EBUS-TBNA biopsy of intrathoracic lymph node: a comparison of conventional Jab method 旋转辅助(RA’s)技术用于胸内淋巴结EBUS-TBNA活检:与传统针刺法的比较

Pleural and Mediastinal Malignancies Pub Date : 2018-09-15 DOI: 10.1183/13993003.congress-2018.pa2875

S. Ra, W. Kwon, Yongjik Lee, C. Park, H. Cha, B. Kang, Taehoon Lee, Y. Jegal, J. Ahn, Y. Chee, K. Seo

引用次数: 0